| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) (NCT05458297) | Merck Sharp & Dohme LLC | 2022-07-21 |
| A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NCT05444322) | He Huang | 2022-07-05 |
| Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma (NCT05025423) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2022-06-21 |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy (NCT05255354) | Adaptive Biotechnologies | 2022-06-01 |
| Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma (NCT05486013) | Peking University Third Hospital | 2022-05-26 |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (NCT05294731) | BeiGene | 2022-05-06 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT04849715) | Incyte Corporation | 2022-03-11 |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy (NCT05064787) | Pack Health | 2022-03-11 |
| Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (NCT04802590) | The Lymphoma Academic Research Organisation | 2022-01-24 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634) | National Cancer Institute (NCI) | 2021-12-16 |
| Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (NCT05214183) | Nordic Lymphoma Group | 2021-12-15 |
| PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (NCT05003141) | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 2021-11-15 |
| A Study of OLR in First-line Treatment of Mantle Cell Lymphoma (NCT05076097) | Tianjin Medical University Cancer Institute and Hospital | 2021-09-30 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas (NCT04883437) | Emory University | 2021-09-03 |
| Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) (NCT04692155) | University of Alabama at Birmingham | 2021-08-31 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678) | Nkarta, Inc. | 2021-08-20 |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (NCT04626791) | Academic and Community Cancer Research United | 2021-08-03 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (NCT04775745) | Newave Pharmaceutical Inc | 2021-07-19 |
| Avo In R/R And Previously Untreated MCL (NCT04855695) | Austin I Kim | 2021-07-02 |
| Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (NCT04765111) | M.D. Anderson Cancer Center | 2021-06-30 |
| Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma (NCT04918940) | Centre Henri Becquerel | 2021-05-21 |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NCT04763083) | NovalGen Ltd. | 2021-05-14 |
| CONFIRM: Magnetic Resonance Guided Radiation Therapy (NCT04368702) | Brigham and Women's Hospital | 2021-05-01 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (NCT05097443) | Shandong Provincial Hospital | 2021-04-15 |
| Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (NCT04783415) | City of Hope Medical Center | 2021-03-26 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (NCT04419389) | Aprea Therapeutics | 2021-03-02 |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (NCT04844086) | Eden BioCell Ltd. | 2021-03-02 |
| Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma (NCT04566887) | University Health Network, Toronto | 2021-03-01 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (NCT05164770) | Shandong Provincial Hospital | 2021-03-01 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma (NCT04736914) | Sun Yat-sen University | 2021-01-31 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma (NCT04718883) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2021-01-13 |
| Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years (NCT05429918) | Peking University Third Hospital | 2020-12-30 |
| Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL (NCT04624958) | Sun Yat-sen University | 2020-12-01 |
| Study of LUCAR-20S in Patients With R/R NHL (NCT04176913) | The First Affiliated Hospital with Nanjing Medical University | 2020-12-01 |
| Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) (NCT04665115) | Academic and Community Cancer Research United | 2020-11-23 |
| Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (NCT04223765) | UNC Lineberger Comprehensive Cancer Center | 2020-11-12 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| The Role of 18F-FDG-PET for Staging and Prognostication (NCT04600804) | Fondazione Italiana Linfomi - ETS | 2020-10-30 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633) | Rutgers, The State University of New Jersey | 2020-10-26 |
| A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole (NCT04564040) | AstraZeneca | 2020-10-12 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma (NCT04189757) | M.D. Anderson Cancer Center | 2020-08-07 |
| Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma (NCT03617484) | University of Michigan Rogel Cancer Center | 2020-07-01 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies (NCT04279405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-06-15 |
| Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (NCT03282396) | M.D. Anderson Cancer Center | 2020-06-08 |
| Atrial Fibrillation in Patients Receiving Ibrutinib (NCT04407845) | European Georges Pompidou Hospital | 2020-05-21 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT04323657) | TCR2 Therapeutics | 2020-03-27 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696) | University of Michigan Rogel Cancer Center | 2020-02-04 |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies (NCT04043845) | Dana-Farber Cancer Institute | 2020-02-03 |
| Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) (NCT04127916) | Samsung Medical Center | 2020-01-30 |
| Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (NCT03834688) | PrECOG, LLC. | 2020-01-13 |
| A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT04115631) | ECOG-ACRIN Cancer Research Group | 2019-12-13 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Italian Observational Study on CAR-T Therapy for Lymphoma (NCT06339255) | Paolo Corradini | 2019-10-30 |
| Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (NCT04116437) | BeiGene | 2019-10-15 |
| Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL (NCT03863184) | Weill Medical College of Cornell University | 2019-10-11 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma (NCT03579927) | M.D. Anderson Cancer Center | 2019-10-03 |
| Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL (NCT03891355) | Fondazione Italiana Linfomi - ETS | 2019-09-30 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04082936) | IGM Biosciences, Inc. | 2019-09-30 |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (NCT04716075) | Polish Lymphoma Research Group | 2019-08-19 |
| Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma (NCT03232307) | M.D. Anderson Cancer Center | 2019-07-01 |
| Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma (NCT04061850) | Samsung Medical Center | 2019-07-01 |
| Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma (NCT03939182) | Memorial Sloan Kettering Cancer Center | 2019-05-29 |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders (NCT03601819) | University of Michigan Rogel Cancer Center | 2019-05-15 |
| Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT03710772) | M.D. Anderson Cancer Center | 2019-05-01 |
| Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (NCT03872180) | Emory University | 2019-04-11 |
| A Disease Registry of Patients With Mantle Cell Lymphoma (NCT03816683) | AstraZeneca | 2019-04-01 |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (NCT03740529) | Loxo Oncology, Inc. | 2019-03-15 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma (NCT03685344) | ADC Therapeutics S.A. | 2019-02-04 |
| BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma (NCT03836768) | Zhejiang DTRM Biopharma | 2019-01-11 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411) | Masonic Cancer Center, University of Minnesota | 2019-01-02 |
| Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma (NCT03523975) | City of Hope Medical Center | 2018-12-24 |
| Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) (NCT03616782) | Ho Sup Lee | 2018-12-24 |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies (NCT03999697) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-12-01 |
| Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma (NCT03684694) | ADC Therapeutics S.A. | 2018-12-01 |
| A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma (NCT03585725) | Weill Medical College of Cornell University | 2018-09-26 |
| Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma (NCT04833504) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2018-09-22 |
| Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results. (NCT04109872) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2018-09-15 |
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (NCT03478514) | Alliance Foundation Trials, LLC. | 2018-09-11 |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR (NCT03676504) | University Hospital Heidelberg | 2018-09-07 |
| A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (NCT03323151) | PrECOG, LLC. | 2018-08-13 |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies (NCT03151057) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-07-31 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors (NCT03010982) | Epizyme, Inc. | 2018-06-20 |
| Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse (NCT03229382) | Polish Lymphoma Research Group | 2018-05-14 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT03410901) | Ronald Levy | 2018-04-09 |
| Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma (NCT03501576) | Emory University | 2018-04-06 |
| A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (NCT03494179) | Beijing InnoCare Pharma Tech Co., Ltd. | 2018-04-02 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603) | Sutro Biopharma, Inc. | 2018-02-22 |